Amyotrophic Lateral Sclerosis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Amylyx Pharmaceuticals, Biogen, AB Sciences, Alexion Pharmaceuticals, BrainStorm Cell Therapeutics

United States, Nevada, Las Vegas, DelveInsight's 'Amyotrophic Lateral Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Amyotrophic Lateral Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Amyotrophic Lateral Sclerosis pipeline domain.
Request for a sample report @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
Over 100+ Amyotrophic Lateral Sclerosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Amyotrophic Lateral Sclerosis market would significantly increase market revenue.
Leading Amyotrophic Lateral Sclerosis companies developing novel drug candidates to improve the Amyotrophic Lateral Sclerosis treatment landscape include Amylyx Pharmaceuticals, Biogen, AB Sciences, Alexion Pharmaceuticals, BrainStorm Cell Therapeutics, and others.
Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include AMX0035, BIIB067, Masitinib, Ravulizumab, Autologous MSC-NTF cells, and others.
Amyotrophic Lateral Sclerosis Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. It leads to the gradual degeneration and death of motor neurons, which are responsible for controlling voluntary muscles. This results in muscle weakness, atrophy, and eventual loss of motor function.

Causes

The exact cause of ALS is not fully understood, but several factors are believed to contribute:

1. Genetic Factors:
- Familial ALS: About 5-10% of ALS cases are inherited, often due to mutations in specific genes such as SOD1, C9orf72, and TARDBP.
- Sporadic ALS: The majority of cases are sporadic and occur without a family history of the disease.

2. Environmental Factors:
- Exposure to Toxins: Pesticides, heavy metals, and other environmental toxins may increase risk.
- Lifestyle Factors: Physical trauma, intense physical activity, and smoking have been studied as potential risk factors.

3. Other Factors:
- Abnormal Protein Aggregation: Accumulation of abnormal proteins in motor neurons may play a role.
- Oxidative Stress: Damage caused by oxidative stress may contribute to neuronal degeneration.

Signs and Symptoms

The symptoms of ALS can vary depending on which motor neurons are affected and the progression of the disease. Common signs and symptoms include:

1. Muscle Weakness:
- Initial Symptoms: Often begins with weakness in the hands, arms, or legs.
- Progression: Weakness spreads to other parts of the body, affecting walking, speaking, and swallowing.

2. Muscle Atrophy:
- Wasting: Muscles become thin and weak as motor neurons degenerate.

3. Twitching and Cramps:
- Fasciculations: Small, involuntary muscle twitches.
- Cramps: Painful muscle cramps and spasms.

4. Difficulty with Speech and Swallowing:
- Dysarthria: Slurred speech or difficulty articulating words.
- Dysphagia: Difficulty swallowing, leading to choking or aspiration.

5. Respiratory Problems:
- Breathing Difficulty: As the disease progresses, respiratory muscles weaken, leading to shortness of breath and respiratory failure.

6. Cognitive and Behavioral Changes:
- Frontotemporal Dementia: Some individuals may experience changes in cognition or behavior, though this is less common.

Diagnosis

Diagnosing ALS involves a combination of clinical evaluation, neurological exams, and diagnostic tests:

1. Clinical Evaluation:
- Medical History: Assessment of symptoms, family history, and progression of the disease.
- Neurological Examination: Evaluation of muscle strength, coordination, reflexes, and sensory function.

2. Diagnostic Tests:
- Electromyography (EMG): Measures electrical activity in muscles and can help detect motor neuron damage.
- Nerve Conduction Studies: Assess the speed and strength of nerve signals.
- Magnetic Resonance Imaging (MRI): To rule out other conditions that may mimic ALS, such as herniated discs or tumors.
- Blood and Urine Tests: To exclude other diseases and conditions.
- Lumbar Puncture: May be performed to analyze cerebrospinal fluid.

3. Genetic Testing:
- For Familial ALS: Identifies specific genetic mutations associated with inherited forms of the disease.

Treatment Options

There is currently no cure for ALS, but treatment focuses on managing symptoms, improving quality of life, and slowing disease progression:

1. Medications:
- Riluzole: The first drug approved for ALS that may help slow progression.
- Edaravone: Another medication that may help slow the decline in physical function.

2. Symptom Management:
- Muscle Spasms and Cramps: Medications like baclofen or tizanidine.
- Pain Management: Analgesics for pain relief.

3. Supportive Therapies:
- Physical Therapy: To maintain muscle strength and flexibility.
- Occupational Therapy: To assist with daily activities and adapt the home environment.
- Speech Therapy: To help with communication difficulties and swallowing problems.
- Respiratory Therapy: To manage breathing issues and assist with ventilation if needed.

4. Nutritional Support:
- Dietary Adjustments: To manage difficulties with swallowing and ensure adequate nutrition.
- Feeding Tubes: May be required for individuals with severe dysphagia.

5. Psychological Support:
- Counseling: To help cope with the emotional and psychological impacts of the disease.
- Support Groups: Connecting with others who have ALS for emotional and practical support.

6. Advanced Care Planning:
- Palliative Care: Focuses on comfort and quality of life, addressing symptoms and end-of-life care preferences.

Prognosis and Follow-Up

ALS is a progressive disease, and its progression varies from person to person. The average life expectancy after diagnosis is about 3-5 years, although some individuals may live longer. Ongoing care, regular follow-ups, and a multidisciplinary approach are essential for managing symptoms and maintaining quality of life.

Amyotrophic Lateral Sclerosis is a challenging condition with a significant impact on individuals and their families. While there is no cure, advancements in treatment and supportive care can help manage symptoms and improve quality of life. Understanding the disease, early diagnosis, and a comprehensive care approach are crucial for optimal management of ALS.
Download sample report @ https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Amyotrophic Lateral Sclerosis Pipeline Analysis: Drug Profile
AMX0035: Amylyx Pharmaceuticals
AMX0035 is an investigational product comprised of two complementary active agents, sodium phenylbutyrate (PB) and taurursodiol (TURSO), which were combined in a co-formulation to reduce neuronal death and dysfunction. AMX0035 was specifically co-formulated and manufactured by Amylyx to ensure proper absorption, exposure, and quality. AMX0035 targets endoplasmic reticulum and mitochondrial dependent neuronal degeneration pathways in ALS and other neurodegenerative diseases. The company has submitted a New Drug Submission (NDS) to Health Canada for AMX0035 (sodium phenylbutyrate (PB)-taurursodiol (TURSO)) for the treatment of ALS.
Discover more about the emerging Amyotrophic Lateral Sclerosis drugs @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Amyotrophic Lateral Sclerosis Key Companies
Amylyx Pharmaceuticals
Biogen
AB Sciences
Alexion Pharmaceuticals
BrainStorm Cell Therapeutics
Amyotrophic Lateral Sclerosis Pipeline Therapies
AMX0035
BIIB067
Masitinib
Ravulizumab
Autologous MSC-NTF cells
Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
Coverage: Global
Key Amyotrophic Lateral Sclerosis Companies: Amylyx Pharmaceuticals, Biogen, AB Sciences, Alexion Pharmaceuticals, BrainStorm Cell Therapeutics, and others
Key Amyotrophic Lateral Sclerosis Pipeline Therapies: AMX0035, BIIB067, Masitinib, Ravulizumab, Autologous MSC-NTF cells, and others
Find out more about the Amyotrophic Lateral Sclerosis treatment options in development @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.